Document is current
Any future updates will be listed below
-
Authors
Gagliardi, Alessia https://orcid.org/0000-0002-6024-503X
Porter, Vanessa L. https://orcid.org/0000-0002-7167-4884
Zong, Zusheng
Bowlby, Reanne
Titmuss, Emma https://orcid.org/0000-0002-1993-6912
Namirembe, Constance https://orcid.org/0000-0001-5979-8465
Griner, Nicholas B.
Petrello, Hilary
Bowen, Jay https://orcid.org/0000-0001-6861-9043
Chan, Simon K.
Culibrk, Luka
Darragh, Teresa M.
Stoler, Mark H.
Wright, Thomas C.
Gesuwan, Patee
Dyer, Maureen A. https://orcid.org/0000-0002-0681-3665
Ma, Yussanne
Mungall, Karen L.
Jones, Steven J. M. https://orcid.org/0000-0003-3394-2208
Nakisige, Carolyn
Novik, Karen
Orem, Jackson https://orcid.org/0000-0002-5366-9010
Origa, Martin
Gastier-Foster, Julie M.
Yarchoan, Robert https://orcid.org/0000-0002-3057-1395
Casper, Corey https://orcid.org/0000-0002-3609-661X
Mills, Gordon B. https://orcid.org/0000-0002-0144-9614
Rader, Janet S.
Ojesina, Akinyemi I.
Gerhard, Daniela S.
Mungall, Andrew J. https://orcid.org/0000-0002-0905-2742
Marra, Marco A. https://orcid.org/0000-0001-7146-7175
- License Information
-
More Information
Article History
Received: 23 October 2019
Accepted: 26 June 2020
First Online: 3 August 2020
Competing interests
: G.B.M. reports the following potentially competing interests: SAB/consultant: AstraZeneca, Chrysallis Biotechnology, ImmunoMET, Ionis, Lilly, PDX Pharmaceuticals, Signalchem Lifesciences, Symphogen, Tarveda, Zentalis; stock/options/financial: Catena Pharmaceuticals, ImmunoMet, SignalChem, Tarveda; licensed technology: HRD assay to Myriad Genetics, DSP patents with Nanostring; sponsored research: Nanostring Center of Excellence, Ionis (provision of tool compounds). R.Y. reports the following potentially competing interests: research support from a CRADA with Celgene/BMS. T.C.W. reports the following potentially competing interests: consultant to Roche, BD and Inovio with respect to HPV diagnostic tests and therapeutic vaccines.
